US Diabetic Retinopathy Market to Exceed $540 Million by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive report on the US Diabetic Retinopathy market. The US market for diabetic retinopathy therapeutics is projected to exceed $540 million by the year 2015. Increasing life expectancy clubbed with concurrent rise in prevalence of diabetes depicts an ominous picture for incidence of diabetic retinopathy in the years to come. Currently, there are no therapeutic drugs approved for treating diabetic retinopathy in the US. This provides ample opportunities for pharmaceutical drug manufacturers.

Diabetic Retinopathy: A US Market Report

Diabetic retinopathy is a form of eye disease that occurs in people suffering from diabetes, leading to severe vision loss, and in some cases, even total blindness. Diabetic retinopathy is a collective term given to diverse abnormalities associated with retinal small blood vessels that are inflicted with diabetes. Vision loss due to diabetic retinopathy is caused by two conditions: Diabetic Macular Edema is a form of non-proliferative diabetic retinopathy where fluid enters the macula, causing it to swell and thus make the vision blurred. Proliferative Diabetic Retinopathy is the final stage of diabetic retinopathy, where problems with circulation of blood cause certain retinal areas to become ischemic (deprived of oxygen). Proliferative Diabetic Retinopathy is a major cause of vision loss in patients with diabetic retinopathy.

Drug therapy for diabetic retinopathy, however, is no longer a dubious proposition, as stated by the new market research report on Diabetic Retinopathy. Drugs such as Arxxant (Eli Lilly), Atacand (Astra Zeneca), Lucentis (Genentech/Novartis), Avastin (Genetech/Roche) and Dexamethasone are all in their late stage development; and some of these drugs are expected to enter the market in the next few years. These drugs, when approved, would open new doors for the treatment of diabetic retinopathy, a disease that is presently being managed only by preventive measures and surgical intervention.

Key players profiled in the report include Allergan, Inc., Eyetech, Inc., Genentech, Inc., Isis Pharmaceuticals, Inc., MacuSight, Inc., OPKO Health, Inc., pSivida Corp., Quark Pharmaceuticals, Inc., Sirnaomics, Inc., and Vitreoretinal Technologies, Inc. among others.

The report titled “Diabetic Retinopathy: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of diabetic retinopathy market scenario, current market trends, research and development, pipeline drugs, clinical trials, recent corporate developments, and focus on major companies. The study analyzes market forecasts in terms of value sales for the US market.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Diabetic_Retinopathy_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media